• Services for Regulatory ATMP Development
    Services for Regulatory ATMP Development

    Living biotherapeutics - Oncolytic viruses - AAV vectors

  • ATMP Biodistribution and Shedding Analysis
    ATMP Biodistribution and Shedding Analysis

    qPCR - CFU determination - Flow cytometry - EliSpot

  • MultiPlex miRNA Biomarker Discovery
    MultiPlex miRNA Biomarker Discovery

    Hydrogel particle-based >65-plex from small samples amounts

  • MultiPlex miRNA Clinical Profiling
    MultiPlex miRNA Clinical Profiling

    Pre-designed & custom >65-plex panels

Accelero Reports 2020 Financial Results and 2021 Forecast

Accelero Bioanalytics GmbH (“Accelero”) announced key figures for the fiscal year 2020 in Germany´s Federal Gazette.

 

Berlin, 13 April 2021

In the light of the global financial crisis triggered by the SARS-CoV-2 pandemic, turnover nevertheless went up by 9% (Previous year 2019: 72%). Sales revenues remain constant with 3% (Previous year 2019: 4%). Approx. 70% of the years´s turnover is created by clients outside Germany.

Accelero currently experiences an extraordinary service order increase. 2021 first quarter results went up by 89% in comparison to the same period last year (Previous year 2020: 0%). Q1 2021 sales revenues accumulated to 14.7%.

The forecast has therefore been raised for the current year 2021. Accelero expects to continue creating high turnover throughout the year, resulting in an overall 30% turnover increase with approx. 12% sales revenues by the end of 2021. An outstanding feature is a contractual agreement covering the GLP-compliant development of a virus-based next generation COVID 19 vaccine.

 

Please click hereto download the press release.